Application and role of fibrates in treatment of primary biliary cholangitis and related mechanisms
10.3969/j.issn.1001-5256.2016.12.038
- VernacularTitle:贝特类药物在原发性胆汁性胆管炎中的应用及作用机制
- Author:
Lihong WU
1
;
Ying HAN
Author Information
1. State Key Laboratory of Cancer Biology, Xijing Hospital of Digestive Disease, Fourth Military Medical University, Xi′an 710032, China
- Publication Type:Research Article
- Keywords:
liver cirrhosis, biliary;
clofibric acid;
ursodeoxycholic acid;
peroxisome proliferator-activated receptors;
review
- From:
Journal of Clinical Hepatology
2016;32(12):2403-2406
- CountryChina
- Language:Chinese
-
Abstract:
Primary biliary cholangitis (PBC) is an autoimmune chronic cholestatic liver disease. Ursodeoxycholic acid (UDCA) is the only safe and effective drug for PBC approved by FDA. To date, there is no unified therapeutic regimen for patients with suboptimal response to UDCA. Fibrates are a class of synthesized ligands of peroxisome proliferator-activated receptors, and recent studies have shown that fibrates may have anticholestatic, anti-inflammatory, and antifibrotic effects. The article reviews the application of fibrates in the treatment of PBC and possible mechanisms.
